fbpx
Menu

Neos Therapeutics Reports Third Quarter 2018 Financial Results

Share

ADHD business grew 9% in prescription volume in the third quarter compared to the previous quarter of 2018 and we reported that the net revenue per pack for both Adzenys XR-ODT and Cotempla XR-ODT was $108. This compares to $95 and $89 respectively for the prior quarter. This improvement in net revenue per pack resulted in part from the programs that we are just beginning to implement to accelerate our path to profitability, said Jerry

McLaughlin, Chief Executive Officer of Neos Therapeutics. With our ADHD products providing a solid and growing base of business, and the additional financial flexibility from our recently completed financing and debt restructuring, we look forward to advancing our whole business and expanding our development pipeline and commercial portfolio. We were pleased to have recently announced the licensing of a pipeline candidate Neos three commercial attention deficit hyperactivity disorder (ADHD) products are Adzenys XR-ODT®, Cotempla XR-ODT® and Adzenys ER which launched in May 2016, …

[Read on via official release]

Source: US SEC
View full document:
8-K_for_Neos_Therapeutics_Inc_8-K-11-09-2018